Harrow, a growing leader in the North American ophthalmic pharmaceutical market, is dedicated to delivering innovative, accessible, and affordable eyecare solutions.

Harrow owns an FDA-Registered 503B Outsourcing Facility and a patient-specific 503A pharmacy.

Mar 28, 2025 · Harrow, Inc. (NASDAQ: HROW) is an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies that are accessible and affordable.

Dec 31, 2024 · NASHVILLE, Tenn.--(BUSINESS WIRE)--Mar. 27, 2025-- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its fourth quarter and audited financial results for the year ended December 31, 2024, on Thursday, March 27, 2025, after the market close.

Jan 29, 2024 · NASHVILLE, Tenn.--(BUSINESS WIRE)--Jan. 29, 2024-- Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the appointments of Adrienne Graves, Ph.D., and Lauren Silvernail to the Company’s Board of …

subsidiary of Harrow, is a direct-to-consumer brand, focused on helping patients manage chronic eye disease using a simple and seamless user experience. Visionology leverages our “Eyecare-as-a-Service™” model to drive value, transparency, and access. Harrow Health also holds non-controlling equity

Mar 27, 2025 · NASHVILLE, Tenn.--(BUSINESS WIRE)--Mar. 27, 2025-- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced results for the fourth quarter and year ended December 31, 2024.

Nov 13, 2023 · Harrow’s. Eyecare Pharmaceuticals. Platform. Highly-trusted, integrated pharmaceutical and pharmacy platform consisting of national sales and customer service teams, automated cGMP drug compounding facilities, and an efficient, scalable, and techenabled -

Harrow, a growing leader in the North American ophthalmic pharmaceutical market, is dedicated to delivering innovative, accessible, and affordable eyecare solutions.

Mar 27, 2025 · Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance